TrialInternational journal of clinical oncology2024

Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors.

Yoichi Naito et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.